Myriad Genetics (MYGN)

• Market cap: $1.13B
• 1 day: -1.04%
• 5 days: -16.51%
• 1 month: -10.35%
• 3 months: -46.89%
• 6 months: -54.26%
• Year to date: -8.22%
• 1 year: -38.11%
• 5 years: -56.86%
• 10 years: -67.38%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Employees: 2,700

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

146% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $1.24M

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

100% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 24

18% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 72

9% more funds holding

Funds holding: 224 [Q2] → 245 (+21) [Q3]

8% more capital invested

Capital invested by funds: $2.3B [Q2] → $2.5B (+$195M) [Q3]

3.61% less ownership

Funds ownership: 104.13% [Q2] → 100.52% (-3.61%) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 5% upside
• Avg. target: $19.50 57% upside
• High target: $24 94% upside

6 analyst ratings

• positive: 0 0%
• neutral: 5 83%
• negative: 1 17%

Stephens & Co. Mason Carrico 68% 1-year accuracy 13 / 19 met price target	61% upside $20	Equal-Weight Reiterated	16 Jan 2025
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target	5% upside $13	Underperform Maintained	13 Dec 2024
UBS Lu Li 100% 1-year accuracy 2 / 2 met price target	45% upside $18	Neutral Initiated	10 Dec 2024
Leerink Partners Puneet Souda 60% 1-year accuracy 3 / 5 met price target	69% upside $21	Market Perform Downgraded	9 Dec 2024
Morgan Stanley Tejas Savant 29% 1-year accuracy 4 / 14 met price target	69% upside $21	Equal-Weight Maintained	18 Nov 2024